Back

A lower dose of liraglutide in patients with metabolic syndrome reduces epicardial adipose tissue, increases aerobic capacity and activates AMPK levels in circulating mononuclear cells.

29 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart: pharmacotherapy (2) Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jorge E Jalil

Catholic University Clinical Hospital, Santiago (Chile)

4 More presentations in this session

Presentation thumbnail
Association between early-stage systemic metabolic disorder and incident cardiometabolic treatment and cardiovascular hospitalisation in Japanese adults
Assistant Professor T. Adachi (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Stress hyperglycemia exceeds known diabetes in predicting in-hospital mortality after acute myocardial infarction: An 11-year national study of 13,099 patients
Professor G. Bajraktari (Pristina, XK)
Abstract Slides Video
Presentation thumbnail
Associations of baseline cumulative and trajectory patterns of the cholesterol HDL glucose index with incident cardiovascular disease
Doctor J. Wei (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
High prevalence of undiagnosed abnormal glucose tolerance in patients with acute myocardial infarction in Northern Sweden
Professor G. Bajraktari (Pristina, XK)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart: pharmacotherapy (2)

The Event

Event poster

ESC Congress 2026

29 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Is there a specific treatment for cardiometabolic syndrome?
31 August 2024
thumbnail
Congress Presentation
Metabolic syndrome contributes to the pulmonary arterial dysfunction in pulmonary hypertension in heart failure with preserved ejection fraction
31 August 2020
thumbnail
Congress Presentation
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
20 June 2025
thumbnail
Congress Presentation
Hemodynamic Changes in response to GLP-1 RA treatment in ICD and CRT patients: Insights from HeartLogic Sensor Data
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources